As global markets kick off the year with a rally, small-cap and value shares are capturing investors' attention, outpacing their larger counterparts. In this context, penny stocks—often representing smaller or newer companies—continue to attract interest for their potential to offer unique opportunities. Although the term "penny stocks" might seem outdated, these investments remain relevant for those seeking under-the-radar companies with solid financial foundations. This article will explore three such penny stocks that stand out for their balance sheet strength and growth potential in today's market landscape.

Top 10 Penny Stocks Globally

Name Share Price Market Cap Financial Health Rating Lever Style (SEHK:1346) HK$1.44 HK$896.85M ★★★★★★ Foresight Group Holdings (LSE:FSG) £4.35 £499.29M ★★★★★★ IVE Group (ASX:IGL) A$2.93 A$451.63M ★★★★★☆ TK Group (Holdings) (SEHK:2283) HK$2.58 HK$2.12B ★★★★★★ Angler Gaming (NGM:ANGL) SEK3.60 SEK269.95M ★★★★★★ Angler Gaming (DB:0QM) €0.31 €227.95M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD3.74 SGD14.72B ★★★★★☆ Integrated Diagnostics Holdings (LSE:IDHC) $0.72 $418.55M ★★★★★☆ Service Stream (ASX:SSM) A$2.15 A$1.32B ★★★★★★ Begbies Traynor Group (AIM:BEG) £1.17 £188.29M ★★★★★☆

Click here to see the full list of 3,532 stocks from our Global Penny Stocks screener.

Let's uncover some gems from our specialized screener.

Guizhou Xinbang Pharmaceutical

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Guizhou Xinbang Pharmaceutical Co., Ltd. manufactures and sells traditional Chinese medicine and other pharmaceutical products in China and internationally, with a market cap of CN¥6.37 billion.

Operations: Guizhou Xinbang Pharmaceutical Co., Ltd. has not reported specific revenue segments.

Market Cap: CN¥6.37B

Guizhou Xinbang Pharmaceutical has demonstrated financial stability with short-term assets of CN¥4.9 billion exceeding both its short and long-term liabilities, and its debt is well covered by operating cash flow at 132.6%. The company reported sales of CN¥4.27 billion for the nine months ending September 2025, though earnings growth has been negative over the past year with a current net profit margin of 1.3%. Despite trading below estimated fair value, challenges include low return on equity at 1.8% and a dividend not well covered by earnings, amid large one-off financial impacts recently recorded.

Unlock comprehensive insights into our analysis of Guizhou Xinbang Pharmaceutical stock in this financial health report. Assess Guizhou Xinbang Pharmaceutical's previous results with our detailed historical performance reports.

Story Continues

SZSE:002390 Debt to Equity History and Analysis as at Jan 2026

Beijing Haixin Energy TechnologyLtd

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Beijing Haixin Energy Technology Co., Ltd. operates in the energy technology sector and has a market cap of CN¥11.94 billion.

Operations: Beijing Haixin Energy Technology Co., Ltd. has not reported any specific revenue segments.

Market Cap: CN¥11.94B

Beijing Haixin Energy Technology Co., Ltd. has shown improvement by reducing its losses over the past five years, despite being unprofitable with a negative return on equity of -5.57%. The company reported sales of CN¥1.94 billion for the nine months ending September 2025, marking a recovery from a net loss to a net income of CN¥57.95 million year-on-year. Short-term assets surpass both short and long-term liabilities, indicating financial stability, while debt levels have decreased significantly over five years to a satisfactory ratio of 1.5%. Recent shareholder meetings focused on extending resolutions for future share offerings to specific parties.

Click here to discover the nuances of Beijing Haixin Energy TechnologyLtd with our detailed analytical financial health report. Gain insights into Beijing Haixin Energy TechnologyLtd's outlook and expected performance with our report on the company's earnings estimates.SZSE:300072 Financial Position Analysis as at Jan 2026

Fuan Pharmaceutical (Group)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Fuan Pharmaceutical (Group) Co., Ltd. engages in the research, development, production, and sale of chemical drugs in China with a market cap of CN¥5.46 billion.

Operations: The company generates revenue of CN¥1.71 billion from its pharmaceutical industry segment.

Market Cap: CN¥5.46B

Fuan Pharmaceutical (Group) Co., Ltd. has experienced a challenging period, with earnings for the nine months ending September 2025 showing a decline in sales to CN¥1.32 billion from CN¥2 billion the previous year and net income dropping to CN¥166.26 million from CN¥301.61 million. Despite this, the company maintains financial stability as its short-term assets exceed both short and long-term liabilities, and it holds more cash than total debt. While its management team is seasoned with an average tenure of 14.7 years, recent negative earnings growth raises concerns about future profitability in a competitive market environment.

Navigate through the intricacies of Fuan Pharmaceutical (Group) with our comprehensive balance sheet health report here. Gain insights into Fuan Pharmaceutical (Group)'s past trends and performance with our report on the company's historical track record.SZSE:300194 Financial Position Analysis as at Jan 2026

Where To Now?

Unlock our comprehensive list of 3,532  Global Penny Stocks by clicking here. Curious About Other Options? Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include SZSE:002390 SZSE:300072 and SZSE:300194.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments